QTQTN motif upstream of the furin-cleavage site plays a key role in SARS-CoV-2 infection and pathogenesis.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
09 08 2022
Historique:
entrez: 26 7 2022
pubmed: 27 7 2022
medline: 29 7 2022
Statut: ppublish

Résumé

The furin cleavage site (FCS), an unusual feature in the SARS-CoV-2 spike protein, has been spotlighted as a factor key to facilitating infection and pathogenesis by increasing spike processing. Similarly, the QTQTN motif directly upstream of the FCS is also an unusual feature for group 2B coronaviruses (CoVs). The QTQTN deletion has consistently been observed in in vitro cultured virus stocks and some clinical isolates. To determine whether the QTQTN motif is critical to SARS-CoV-2 replication and pathogenesis, we generated a mutant deleting the QTQTN motif (ΔQTQTN). Here, we report that the QTQTN deletion attenuates viral replication in respiratory cells in vitro and attenuates disease in vivo. The deletion results in a shortened, more rigid peptide loop that contains the FCS and is less accessible to host proteases, such as TMPRSS2. Thus, the deletion reduced the efficiency of spike processing and attenuates SARS-CoV-2 infection. Importantly, the QTQTN motif also contains residues that are glycosylated, and disruption of its glycosylation also attenuates virus replication in a TMPRSS2-dependent manner. Together, our results reveal that three aspects of the S1/S2 cleavage site-the FCS, loop length, and glycosylation-are required for efficient SARS-CoV-2 replication and pathogenesis.

Identifiants

pubmed: 35881779
doi: 10.1073/pnas.2205690119
pmc: PMC9371735
doi:

Substances chimiques

Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Furin EC 3.4.21.75

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2205690119

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI153602
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI145400
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI120942
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060549
Pays : United States

Références

Nat Protoc. 2021 Mar;16(3):1761-1784
pubmed: 33514944
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Front Med (Lausanne). 2022 Jan 06;8:822633
pubmed: 35071285
mBio. 2013 Apr 30;4(3):e00165-13
pubmed: 23631916
Front Chem. 2021 Nov 19;9:767448
pubmed: 34869209
J Virol. 2020 Aug 17;94(17):
pubmed: 32571797
PLoS Pathog. 2021 Aug 30;17(8):e1009857
pubmed: 34460863
J Virol. 2008 Sep;82(17):8721-32
pubmed: 18579604
Methods. 2019 Feb 15;155:20-29
pubmed: 30625385
Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2205690119
pubmed: 35881779
PLoS Pathog. 2021 Apr 22;17(4):e1009500
pubmed: 33886690
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Curr Protoc Bioinformatics. 2012 Dec;Chapter 13:Unit13.20
pubmed: 23255153
J Virol. 2014 Apr;88(8):4251-64
pubmed: 24478444
J Gen Virol. 2020 Sep;101(9):925-940
pubmed: 32568027
Elife. 2021 Sep 28;10:
pubmed: 34581669
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Emerg Microbes Infect. 2020 Dec;9(1):837-842
pubmed: 32301390
Cell. 2021 Sep 16;184(19):4848-4856
pubmed: 34480864
PLoS Negl Trop Dis. 2020 Jul 20;14(7):e0007960
pubmed: 32687500
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
J Mol Biol. 2015 Aug 14;427(16):2610-6
pubmed: 26116762
Nat Microbiol. 2021 Jul;6(7):899-909
pubmed: 33907312
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
Virus Genes. 2022 Feb;58(1):53-58
pubmed: 34839413
Anal Chem. 2021 Feb 2;93(4):2003-2009
pubmed: 33406838
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Antiviral Res. 2020 Apr;176:104742
pubmed: 32057769
Nucleic Acids Res. 2017 Jul 7;45(12):e112
pubmed: 28449108
mBio. 2021 May 11;12(3):
pubmed: 33975939
J Proteome Res. 2018 Aug 3;17(8):2861-2869
pubmed: 29966421

Auteurs

Michelle N Vu (MN)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.

Kumari G Lokugamage (KG)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.

Jessica A Plante (JA)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555.

Dionna Scharton (D)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555.

Aaron O Bailey (AO)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555.

Stephanea Sotcheff (S)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555.

Daniele M Swetnam (DM)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555.

Bryan A Johnson (BA)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.

Craig Schindewolf (C)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.

R Elias Alvarado (RE)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX.

Patricia A Crocquet-Valdes (PA)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555.

Kari Debbink (K)

Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21211.

Scott C Weaver (SC)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555.
Center for Biodefense and Emerging Infectious Disease, University of Texas Medical Branch, Galveston, TX 77555.

David H Walker (DH)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555.
Center for Biodefense and Emerging Infectious Disease, University of Texas Medical Branch, Galveston, TX 77555.

William K Russell (WK)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555.

Andrew L Routh (AL)

Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555.
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555.

Kenneth S Plante (KS)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555.

Vineet D Menachery (VD)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555.
Center for Biodefense and Emerging Infectious Disease, University of Texas Medical Branch, Galveston, TX 77555.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH